Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 11 | $51,294,396 |
Sells | 143 | $59,705,589 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
16 May 2024 19:52 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 16 May 2024 | Sale | 44,746 | 9.0581 | 405,314 | I |
16 May 2024 19:52 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 15 May 2024 | Sale | 2,766 | 9.0403 | 25,005 | I |
16 May 2024 19:52 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 15 May 2024 | Sale | 2,381 | 9.0547 | 21,559 | I |
16 May 2024 19:52 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 14 May 2024 | Sale | 2,884 | 9.0058 | 25,973 | I |
16 May 2024 19:52 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 14 May 2024 | Sale | 2,873 | 9.0084 | 25,881 | I |
09 May 2024 18:57 | SPRY | ARS Pharmaceuticals Inc | LOWENTHAL RICHARD E | PRESIDENT AND CEO, 10% | 07 May 2024 | Sale | 50,000 | 9.3446 | 467,230 | I |
09 May 2024 18:57 | SPRY | ARS Pharmaceuticals Inc | LOWENTHAL RICHARD E | PRESIDENT AND CEO, 10% | 07 May 2024 | Sale | 50,000 | 9.3427 | 467,135 | I |
09 May 2024 18:59 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 07 May 2024 | Sale | 50,000 | 9.3446 | 467,230 | I |
09 May 2024 18:59 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 07 May 2024 | Sale | 50,000 | 9.3427 | 467,135 | I |
17 Apr 2024 18:40 | SPRY | ARS Pharmaceuticals Inc | LOWENTHAL RICHARD E | PRESIDENT AND CEO, 10% | 16 Apr 2024 | Sale | 50,000 | 9.2797 | 463,985 | I |
17 Apr 2024 18:40 | SPRY | ARS Pharmaceuticals Inc | LOWENTHAL RICHARD E | PRESIDENT AND CEO, 10% | 16 Apr 2024 | Sale | 50,000 | 9.2804 | 464,020 | I |
17 Apr 2024 18:42 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 16 Apr 2024 | Sale | 50,000 | 9.2797 | 463,985 | I |
17 Apr 2024 18:42 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 16 Apr 2024 | Sale | 50,000 | 9.2804 | 464,020 | I |
10 Apr 2024 17:39 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 09 Apr 2024 | Sale | 50,000 | 9.277 | 463,850 | I |
10 Apr 2024 17:39 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 09 Apr 2024 | Sale | 50,000 | 9.2777 | 463,885 | I |
10 Apr 2024 17:36 | SPRY | ARS Pharmaceuticals Inc | LOWENTHAL RICHARD E | PRESIDENT AND CEO, 10% | 09 Apr 2024 | Sale | 50,000 | 9.277 | 463,850 | I |
10 Apr 2024 17:36 | SPRY | ARS Pharmaceuticals Inc | LOWENTHAL RICHARD E | PRESIDENT AND CEO, 10% | 09 Apr 2024 | Sale | 50,000 | 9.2777 | 463,885 | I |
27 Mar 2024 19:37 | SPRY | ARS Pharmaceuticals Inc | RA CAPITAL MANAGEMENT, L.P. | Director , 10% | 27 Mar 2024 | Purchase | 505,954 | 9.79 | 4,953,290 | I |
27 Mar 2024 19:37 | SPRY | ARS Pharmaceuticals Inc | RA CAPITAL MANAGEMENT, L.P. | Director , 10% | 25 Mar 2024 | Purchase | 437,600 | 9.06 | 3,964,656 | I |
27 Mar 2024 19:37 | SPRY | ARS Pharmaceuticals Inc | RA CAPITAL MANAGEMENT, L.P. | Director , 10% | 26 Mar 2024 | Purchase | 457,745 | 9.55 | 4,371,465 | I |
26 Mar 2024 18:47 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 25 Mar 2024 | Sale | 47,632 | 9.1236 | 434,575 | I |
26 Mar 2024 18:47 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 25 Mar 2024 | Sale | 47,635 | 9.1238 | 434,612 | I |
26 Mar 2024 18:47 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 22 Mar 2024 | Sale | 1,326 | 9.0132 | 11,952 | I |
26 Mar 2024 18:47 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 22 Mar 2024 | Sale | 1,017 | 9.0298 | 9,183 | I |
26 Mar 2024 18:48 | SPRY | ARS Pharmaceuticals Inc | LOWENTHAL RICHARD E | PRESIDENT AND CEO, 10% | 25 Mar 2024 | Sale | 47,632 | 9.1236 | 434,575 | I |
26 Mar 2024 18:48 | SPRY | ARS Pharmaceuticals Inc | LOWENTHAL RICHARD E | PRESIDENT AND CEO, 10% | 25 Mar 2024 | Sale | 47,635 | 9.1238 | 434,612 | I |
26 Mar 2024 18:48 | SPRY | ARS Pharmaceuticals Inc | LOWENTHAL RICHARD E | PRESIDENT AND CEO, 10% | 22 Mar 2024 | Sale | 1,326 | 9.0132 | 11,952 | I |
26 Mar 2024 18:48 | SPRY | ARS Pharmaceuticals Inc | LOWENTHAL RICHARD E | PRESIDENT AND CEO, 10% | 22 Mar 2024 | Sale | 1,017 | 9.0298 | 9,183 | I |
21 Mar 2024 21:50 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 21 Mar 2024 | Sale | 372 | 9 | 3,348 | I |
21 Mar 2024 21:50 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 21 Mar 2024 | Sale | 100 | 9 | 900 | I |
21 Mar 2024 21:50 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 19 Mar 2024 | Sale | 942 | 9.0376 | 8,513 | I |
21 Mar 2024 21:50 | SPRY | ARS Pharmaceuticals Inc | TANIMOTO SARINA | CHIEF MEDICAL OFFICER, 10% | 19 Mar 2024 | Sale | 976 | 9.0273 | 8,811 | I |
21 Mar 2024 21:51 | SPRY | ARS Pharmaceuticals Inc | LOWENTHAL RICHARD E | PRESIDENT AND CEO, 10% | 21 Mar 2024 | Sale | 100 | 9 | 900 | I |
21 Mar 2024 21:51 | SPRY | ARS Pharmaceuticals Inc | LOWENTHAL RICHARD E | PRESIDENT AND CEO, 10% | 21 Mar 2024 | Sale | 372 | 9 | 3,348 | I |
21 Mar 2024 21:51 | SPRY | ARS Pharmaceuticals Inc | LOWENTHAL RICHARD E | PRESIDENT AND CEO, 10% | 19 Mar 2024 | Sale | 942 | 9.0376 | 8,513 | I |
21 Mar 2024 21:51 | SPRY | ARS Pharmaceuticals Inc | LOWENTHAL RICHARD E | PRESIDENT AND CEO, 10% | 19 Mar 2024 | Sale | 976 | 9.0273 | 8,811 | I |
05 Sep 2023 20:04 | SPRY | ARS Pharmaceuticals Inc | SHAWVER LAURA | Director | 01 Sep 2023 | Sale | 100,000 | 7.7052 | 770,520 | D |
31 Aug 2023 17:26 | SPRY | ARS Pharmaceuticals Inc | ORBIMED ADVISORS LLC | Director | 29 Aug 2023 | Purchase | 500,000 | 6.2 | 3,100,000 | I |
31 Aug 2023 17:26 | SPRY | ARS Pharmaceuticals Inc | RA CAPITAL MANAGEMENT, L.P. | Director | 29 Aug 2023 | Purchase | 3,750,000 | 6.2 | 23,250,000 | I |
31 Aug 2023 17:18 | SPRY | ARS Pharmaceuticals Inc | THOMPSON PETER A. | Director | 29 Aug 2023 | Purchase | 500,000 | 6.2 | 3,100,000 | I |
07 Aug 2023 17:05 | SPRY | ARS Pharmaceuticals Inc | SHAWVER LAURA | Director | 04 Aug 2023 | Sale | 18,897 | 7.0631 | 133,471 | D |
07 Aug 2023 17:05 | SPRY | ARS Pharmaceuticals Inc | SHAWVER LAURA | Director | 03 Aug 2023 | Sale | 26,107 | 7.0103 | 183,018 | D |
03 Aug 2023 18:03 | SPRY | ARS Pharmaceuticals Inc | SHAWVER LAURA | Director | 02 Aug 2023 | Sale | 36,281 | 7.0909 | 257,265 | D |
03 Aug 2023 18:03 | SPRY | ARS Pharmaceuticals Inc | SHAWVER LAURA | Director | 01 Aug 2023 | Sale | 18,715 | 7.1908 | 134,576 | D |
07 Jul 2023 20:16 | SPRY | ARS Pharmaceuticals Inc | SHAWVER LAURA | Director | 07 Jul 2023 | Sale | 8,858 | 6.364 | 56,372 | D |
02 Jun 2023 19:48 | SPRY | ARS Pharmaceuticals Inc | SHAWVER LAURA | Director | 02 Jun 2023 | Sale | 26,941 | 6.95 | 187,240 | D |
02 Jun 2023 19:48 | SPRY | ARS Pharmaceuticals Inc | SHAWVER LAURA | Director | 01 Jun 2023 | Sale | 73,059 | 6.8 | 496,801 | D |
10 May 2023 16:53 | SPRY | ARS Pharmaceuticals Inc | SHAWVER LAURA | Director | 09 May 2023 | Sale | 42,900 | 5.31 | 227,799 | D |
10 May 2023 16:53 | SPRY | ARS Pharmaceuticals Inc | SHAWVER LAURA | Director | 08 May 2023 | Sale | 57,100 | 6.16 | 351,736 | D |
10 May 2023 16:53 | SPRY | ARS Pharmaceuticals Inc | SHAWVER LAURA | Director | 09 Nov 2022 | Sale | 43,896 | 4.58 | 201,044 | D |
01 Dec 2022 16:31 | SPRY | ARS Pharmaceuticals Inc | SCOTT KATHLEEN D. | Chief Financial Officer | 29 Nov 2022 | Purchase | 8,250 | 6.2432 | 51,506 | I |
06 Jul 2023 20:55 | SPRY | ARS Pharmaceuticals Inc | SHAWVER LAURA | Director | 06 Jul 2023 | Sale | 33,510 | 6.343 | 212,554 | D |
06 Jul 2023 20:55 | SPRY | ARS Pharmaceuticals Inc | SHAWVER LAURA | Director | 05 Jul 2023 | Sale | 31,112 | 6.414 | 199,552 | D |
06 Jul 2023 20:55 | SPRY | ARS Pharmaceuticals Inc | SHAWVER LAURA | Director | 03 Jul 2023 | Sale | 26,520 | 6.725 | 178,347 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)